IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization

Citation:

Zafira Castaño, Beatriz P San Juan, Asaf Spiegel, Ayush Pant, Molly J DeCristo, Tyler Laszewski, Jessalyn M Ubellacker, Susanne R Janssen, Anushka Dongre, Ferenc Reinhardt, Ayana Henderson, Ana Garcia Del Rio, Ann M Gifford, Zachary T Herbert, John N Hutchinson, Robert A Weinberg, Christine L Chaffer, and Sandra S McAllister. 2018. “IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization.” Nat Cell Biol, 20, 9, Pp. 1084-1097.

Abstract:

Lack of insight into mechanisms governing breast cancer metastasis has precluded the development of curative therapies. Metastasis-initiating cancer cells (MICs) are uniquely equipped to establish metastases, causing recurrence and therapeutic resistance. Using various metastasis models, we discovered that certain primary tumours elicit a systemic inflammatory response involving interleukin-1β (IL-1β)-expressing innate immune cells that infiltrate distant MIC microenvironments. At the metastatic site, IL-1β maintains MICs in a ZEB1-positive differentiation state, preventing MICs from generating highly proliferative E-cadherin-positive progeny. Thus, when the inherent plasticity of MICs is impeded, overt metastases cannot be established. Ablation of the pro-inflammatory response or inhibition of the IL-1 receptor relieves the differentiation block and results in metastatic colonization. Among patients with lymph node-positive breast cancer, high primary tumour IL-1β expression is associated with better overall survival and distant metastasis-free survival. Our data reveal complex interactions that occur between primary tumours and disseminated MICs that could be exploited to improve patient survival.